Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial

Autor: Petrylak, Daniel P, Vogelzang, Nicholas J, Budnik, Nikolay, Wiechno, Pawel Jan, Sternberg, Cora N, Doner, Kevin, Bellmunt, Joaquim, Burke, John M, de Olza, Maria Ochoa, Choudhury, Ananya, Gschwend, Juergen E, Kopyltsov, Evgeny, Flechon, Aude, Van As, Nicolas, Houede, Nadine, Barton, Debora, Fandi, Abderrahim, Jungnelius, Ulf, Li, Shaoyi, de Wit, Ronald, Fizazi, Karim
Zdroj: In The Lancet Oncology April 2015 16(4):417-425
Databáze: ScienceDirect